In a pivotal moment for the American cannabis sector, the U.S. Department of Health and Human Services (HHS) has proposed a reclassification of cannabis to the DEA. This could shift cannabis from its current Schedule I status, bringing potential upheaval in the perception and market dynamics of the plant.
At a recent virtual event hosted by Benzinga's Javier Hasse and led by VP of Virtual Events Matt Steinmetz under the sponsorship of FundCanna, industry experts delved into the profound implications of this recommendation, tracing the trajectory of cannabis regulation.
If you're keen to delve deeper into these topics, don't miss the upcoming Benzinga Cannabis Capital Conference in Chicago. Mark your calendar for September 27-28.
See Also: Trulieve CEO: Federal Rescheduling Could Change Heavy Tax Burden For Cannabis Industry
‘Legalization Means Regulation’
"Legalization means regulation, right? So when you say legalize, what you're saying is regulate," noted webinar moderator and Benzinga's head of cannabis content Javier Hasse.
Looking back, David Traylor, Sr. managing director at Golden Eagle Partners, highlighted the U.N. single convention, the inception of the Controlled Substance Act (CSA), and current DEA rulings. "The Shafer Commission once deemed marijuana as not particularly harmful," addressing the enduring discussion about cannabis' societal placement.
Hunter Land, Ph.D. VP of Research & Development at Biopharmaceutical Research Company brought a scientific ...